1. Home
  2. CYTK vs MCY Comparison

CYTK vs MCY Comparison

Compare CYTK & MCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • MCY
  • Stock Information
  • Founded
  • CYTK 1997
  • MCY 1961
  • Country
  • CYTK United States
  • MCY United States
  • Employees
  • CYTK N/A
  • MCY N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • MCY Property-Casualty Insurers
  • Sector
  • CYTK Health Care
  • MCY Finance
  • Exchange
  • CYTK Nasdaq
  • MCY Nasdaq
  • Market Cap
  • CYTK 4.6B
  • MCY 4.3B
  • IPO Year
  • CYTK 2004
  • MCY N/A
  • Fundamental
  • Price
  • CYTK $60.16
  • MCY $83.59
  • Analyst Decision
  • CYTK Strong Buy
  • MCY Strong Buy
  • Analyst Count
  • CYTK 15
  • MCY 1
  • Target Price
  • CYTK $76.73
  • MCY $100.00
  • AVG Volume (30 Days)
  • CYTK 1.7M
  • MCY 225.2K
  • Earning Date
  • CYTK 11-05-2025
  • MCY 11-04-2025
  • Dividend Yield
  • CYTK N/A
  • MCY 1.52%
  • EPS Growth
  • CYTK N/A
  • MCY N/A
  • EPS
  • CYTK N/A
  • MCY 7.93
  • Revenue
  • CYTK $87,211,000.00
  • MCY $5,814,768,000.00
  • Revenue This Year
  • CYTK $363.61
  • MCY $7.13
  • Revenue Next Year
  • CYTK $64.33
  • MCY $7.60
  • P/E Ratio
  • CYTK N/A
  • MCY $10.54
  • Revenue Growth
  • CYTK 2609.26
  • MCY 5.93
  • 52 Week Low
  • CYTK $29.31
  • MCY $44.19
  • 52 Week High
  • CYTK $64.13
  • MCY $87.67
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 55.21
  • MCY 61.18
  • Support Level
  • CYTK $58.05
  • MCY $74.29
  • Resistance Level
  • CYTK $61.29
  • MCY $84.00
  • Average True Range (ATR)
  • CYTK 2.60
  • MCY 2.13
  • MACD
  • CYTK -0.48
  • MCY 0.44
  • Stochastic Oscillator
  • CYTK 57.88
  • MCY 80.71

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About MCY Mercury General Corporation

Mercury General Corp is an insurance holding company. It is engaged in writing personal automobile insurance and provides related property and casualty insurance products. The Company offers the following types of automobile coverage: collision, property damage, bodily injury ("BI"), comprehensive, personal injury protection ("PIP"), underinsured and uninsured motorist, and other hazards. The Company offers the following types of homeowners coverage: dwelling, liability, personal property, and other coverages.

Share on Social Networks: